Medicare Proposes to Sharply Limit Coverage of the Alzheimer’s Drug Aduhelm
The F.D.A. also required Biogen to conduct another clinical trial to determine if the drug provided any evidence of benefit. In the years it will take for that trial to be completed, Aduhelm will be available to patients. Medicare’s coverage decision is considered pivotal to the future of Aduhelm, which is priced at $28,200 a…